Effient(R) (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study

INDIANAPOLIS and TOKYO--16 Aug--PRNewswire-AsiaNet/ InfoQuest Analysis evaluated efficacy and safety among three patient sub-groups A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study - those identified as the "core clinical cohort" population - showed that treatment with prasugrel (in combination with aspirin) was associated with a 26 percent relative risk reduction in the combined primary endpoint of cardiovascular death, myocardial infarction or stroke, compared to treatment with clopidogrel (8.3 percent vs. 11.0 percent, respectively, p